Vanda Pharmaceuticals Inc. (Vanda), a biopharmaceutical company, announced that a Fanapt patent, number 8,999,638 ('638 patent), is now listed in the US Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The '638 patent was issued by the United States Patent and Trademark Office on April 7, 2015 and expires in October 2030.
Prior to this newly listed '638 patent, the Fanapt Orange Book listed patents were the US composition of matter patent and the '610 patent, expected to expire in November 2016 and November 2027, respectively.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.